All In Biotech

Drug Trial Radar · NCT05646758

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects

A Phase I Clinical Trial Evaluating the Tolerance and Pharmacokinetics of TQB2934 for Injection in Multiple Myeloma Subjects

Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

140

Planned (sponsor's estimate)

Start

Mar 17, 2023

Primary completion

Oct 2024

Study completion Oct 2025

Sponsor

Sponsor type
Industry
First posted
Dec 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen) double-specific antibody,and the isoform is IgG1 (Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.TQB2934 for injection is planned for the treatment of patients with multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • TQB2934 injectionDrug

    TQB2934 is an anti-CD3×BCMA double-specific antibody,which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: Up to 18 months
  2. Maximum Tolerated Dose (MTD)Time frame: Up to 18 months
  3. Incidence and severity of serious adverse events (AEs)Time frame: Up to 18 months
  4. Incidence and severity of adverse events (AEs)Time frame: Up to 18 months
  5. Incidence and severity abnormal laboratory test valueTime frame: Up to 18 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-Sen University Cancer Canter

    Guangzhou, Guangdong, China · Recruiting

  • The Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Shandong First Medical University Affiliated Tumor Hospital

    Jinan, Shandong, China · Recruiting

  • Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.